Pharma major Lupin’s subsidiary, Lupin Pharmaceuticals Inc. has received final approval for its Pergabalin capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from United States Food Drugs Administration (US FDA) to market a generic version of C P Pharmaceuticals CV, Lyrica (Pregabalin) capsules.

Lupin’s Pergabalin capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg are the AB-rated generic equivalent of Lyrica capsules, which is indicated for neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures and fibromyalgia.

Lyrica capsules had annual US sales of approximately $1.8 billion for the twelve months ending March 2012, as per IMS Health sales data.